secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cardiff Oncology, Inc. (CRDF)
CIK:        0001213037
Form:       8-K
Filed at:   2022-04-12T23:59:59+00:00
Accession:  0001628280-22-008987
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cardiff Oncology CMO Katherine Ruffner departs; Sandra Silberman named interim senior medical advisor
--------------------------------------------------------------------------------

- CMO Katherine Ruffner leaving April 22, 2022; will provide transitional support.
- Separation agreement includes $75,000 cash payment, base salary, unused PTO, expense reimbursement.
- Sandra Silberman, former chief medical advisor (2017-2021), returns as senior medical advisor on interim basis.
- Silberman has experience at Pfizer, Novartis, Eisai; currently CMO at Moleculin Biotech and CNS Pharmaceuticals.
- CEO states clinical trials remain on track and on schedule.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213037/000162828022008987/0001628280-22-008987-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213037/000162828022008987/crdf-20220407.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-008987

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer